Full-length article

Effects of intrathecal 6-hydroxydopamine, α_1 and α_2 adrenergic receptor antagonists on antinociception of propofol in mice

Zhi-jun GE^{1,2}, Yin-ming ZENG¹, Yong-fei TAN²

¹Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical College, Xuzhou 221002, China; ²Jiangsu Province People's Hospital of Yixing, Yixing 214200, China

Key words

propofol; spinal cord; antinociception; prazosin; yohimbine; norepinephrine

¹Correspondence to Prof Yin-ming ZENG. Phn 86-516-580-2018. Fax 86-516-5708, ext 135. E-mail zym_xzmc@163.com

Received 2004-07-21 Accepted 2004-10-19

doi: 10.1111/j.1745-7254.2005.00033.x

Abstract

Aim: To investigate the relationship between spinal cord norepinephrine, α_1 and α_2 adrenergic receptors and antinociception of propofol in mice. Methods: Kunming mice were used. Antinociceptive tests were investigated with the tailimmersion test and the acetic acid-induced writhing test. The effects of subcutaneous (sc), intrathecal (ith) and intracerebroventricular (icv) injection propofol on pain threshold were observed. The influences of pretreatment with ith 6hydroxydopamine, $\alpha_1 R$ antagonist prazosin, or $\alpha_2 R$ antagonist yohimbine on the antinociception of propofol were studied. Results: Significant antinociception was produced by propofol (25, 50 mg/kg, sc) and propofol (20, 40 µg, ith) in tailimmersion test and acetic the acid-induced writhing test (P<0.05 or P<0.01). Icv propofol (10, 20, and 40 µg) did not produce any effect on pain threshold in mice (P>0.05). The 6-hydroxydopamine (5 and 10 µg), prazosin (5 and 10 µg), or yohimbine (5 and 10 µg) ith alone did not affect basal tai-flick latency (TFL) in conscious mice, but significantly reduced the TFL as measured by tail-immersion test in propofol (50 mg/kg, sc)-treated mice, compared with basal TFL and vehicle groups (P < 0.05 or P < 0.01). **Conclusion:** The spinal cord is a target of propofol antinociception. In mice propofol antinociception is partly mediated by spinal norepinephrine, $\alpha_1 R$ and $\alpha_2 R$.

Introduction

Propofol (2,6-diisopropylphenol, Diprivan) is widely used in the clinical setting as an iv anesthetic. Its antinociceptive effect results from an excitation of spinal GABA_A receptors^[1] and an inhibition of spinal NMDA, AMPA receptors^[2], *etc.* A study by Antognini *et al* also suggested that propofol has a direct depressant effect on dorsal horn neuronal responses to noxious stimulation^[3]. Therefore, these studies suggested a spinal mediation of propofolinduced antinociception. However there was also a study that concluded that propofol could control pain and this action might be centrally modulated through the opioid system rather than at the level of the spinal cord^[4]. Therefore the contribution of supraspinal sites versus spinal sites to the antinociception of propofol is still unclear.

The mechanism whereby stimulation of opiate receptors

in supraspinal regions produced analgesia has been extensively investigated and appeared, in part, to involve a descending noradrenergic pathway^[5,6]. Norepinephrine (NE) is a major neurotransmitter in the descending inhibition of nociceptive transmission. Available evidence suggests that at the level of the spinal cord, there appear to be at least two neuronal systems that are involved. The first is the direct presynaptic inhibition of the nociception of the primary afferent neurons or postsynaptic inhibition of the second order neurons through activation of α_2 adrenergic receptor $(\alpha_2 Rs)^{[7,8]}$. The second is the indirect activation of the inhibitory interneurons through $\alpha_1 Rs$ located on these neurons^[8,9].

Based on these observations, in the present study, we injected propofol systemically, intrathecally, or intracerebroventricularly to further examine the role of spinal and supraspinal sites in mediating the antinociception of propofol. We sought evidences of the involvement of spinal NE, $\alpha_1 R$, and $\alpha_2 R$ in the antinociception induced by sc propofol in mice.

Materials and methods

Animals With the approve of the Committee of Animal Research of Xuzhou Medical College, we conducted experiments on Kunming mice (22±3 g, Grade II, Certificate No SCXK-SU-2002-0022) of both sexes, obtained from the Laboratory Animal Center of Xuzhou Medical College, housed individually in a temperature-controlled 22±2 °C room with a 12-h light-dark cycle and given free access to food and water. Each animal was used in only one experiment.

Chemicals Propofol and vehicle (10% intralipid) were supplied by the AstraZeneca Company. Prazosin, yohimbine and 6-hydroxydopamine (6-OHDA) were purchased from Sigma-Alexis (USA). Ice acetic acid was produced by Beijing Chemical Factory. All drugs were all freshly prepared. Prazosin was first dissolved in 50% dimethyl sulfoxide (Me₂SO) in normal saline (NS) and the solution was diluted with NS. Yohimbine was dissolved in NS. 6-OHDA was dissolved in a saline vehicle (0.02% ascorbic acid in 0.9% saline). Systemic drug administration was sc performed in a single volume of 0.01 L/kg.

Intracerebroventricular injection in conscious mice^[10] A 25-gauge needle was inserted in the left lateral ventricle of the brain with the following coordinates: left 2 mm of sagittal suture on the linking line of ears, and 2 mm down the skull surface. Volume of icv injections was 5 μ L. The proper position of the icv localization was verified at the end of each protocol by injection of methylene blue staining with the same coordinates.

Intrathecal injection in conscious mice^[2] A 25-gauge needle was inserted at L_5-L_6 intrathecal space. Ith placement was confirmed by a sudden lateral movement of the tail. All mice were injected with a 5-µL volume of drugs or vehicles and, after allowing 5 s for the injectant to disperse, the needle was slowly withdrawn. While developing this technique we injected 5 µL of 2% lidocaine ith in 10 mice, which consistently caused a transient hind-paw paralysis.

Tail-immersion test^[11] The caudal 1/3 of tails of mice were immersed in 48±0.5 °C water. The time for the mice to remove their tails from the water was expressed as the tailflick latency (TFL). All mice were tested twice at a 5-min interval and the mean value was considered as the basal pain threshold. A cut-off time of 60 s was used to minimize damage to the skin of the tail. The influences of sc propofol (12.5, 25, and 50 mg/kg, n=10) alone on the TFL and the effects of pretreatment with ith prazosin and yohimbine 10 min before propofol (50 mg/kg, sc, n=10) injection on the TFL were investigated, respectively. To demonstrate the sc propofol-induced prolongation of TFL was not caused by its hypnotic effect, the time courses for the development of propofol-induced hypnosis were established. The loss of righting reflex was assessed by placing the mice on their backs and determining if the animals could right themselves within 30 s.

In a separate study, groups of mice were pretreated intrathecally with 6-OHDA (5, 10, and 20 µg) for 3 d (one injection in all). The dosing scheme of 6-OHDA was chosen according to the study by Hung *et al*^[12] with minor modification. The tail-immersion test was performed on d 4 and the effect of propofol (50 mg/kg, sc, n=10) on TFL was observed.

Acetic acid-induced writhing test^[2] Mice were administered NS, intralipid or propofol 30 min before ip injection of 0.9% ice acetic acid in a volume of 10 mL/kg. The number, latency and times of writhing mice were recorded within 15 min after the last injection.

Statistical analysis All data were present as mean \pm SD. Statistical comparisons in each group were performed by one-way analysis of variance (ANOVA) followed by *t*-test. Difference was considered to be significant at *P*<0.05.

Results

Hypnotic and antinociceptive effects of propofol were temporarily uncoupled Propofol 12.5, 25 mg/kg sc had no appreciable effect on the general behavior in mice. After 2–5 min treatment of propofol (50 mg/kg, sc), mice showed slight sedation. The sedative effect reached maximum after 5 min of propofol injection, and 20% mice (2/10) developed a loss of righting reflex; however, after this time there was no significant increase in TFL. In contrast, sc propofol resulted in a significant increase in TFL 10–30 min after its injection with the peak effect at 10 min (P<0.01, Table 1), but after 30 min, all mice remained righting reflex and there was no appreciable effect on general behavior. Neither propofol ith nor icv resulted in any appreciable abnormal behavior.

Effects of propofol on pain threshold in tail-immersion test and acetic acid-induced writhing test in mice There was no significant change of TFL before and after sc, ith, or icv injection of 10% intralipid compared with the NS (sc, ith, or icv) group, respectively in tail-immersion test (P> 0.05, Table 1). Propofol (12.5 mg/kg, sc) and propofol (5 µg, ith) showed no effect on TFL. However, propofol (25 and 50 mg/kg, sc) and propofol (10, 20 µg, ith) increased

Table 1.	Effect of propofol on the tail-flick latency (TFL) in tail-immersion test on mice	n = 10.	Mean±SD.	^b <i>P</i> <0.05, ^c <i>P</i> <0	.01 vs baseline.	°P<0.05,
^f P<0.01	vs NS (sc). ^h P<0.05, ⁱ P<0.01 vs NS (ith).					

Groups		TFL/s					
	Before treated			After treated			
		5 min	10 min	20 min	30 min	40 min	
Normal saline(sc)	11.3±1.3	10.2 ± 1.7	12.5±2.3	10.9±1.9	13±3	12.2±2.7	
Intralipid (sc)	11.5 ± 0.8	10.8±1.3	10.8±1.5	11±3	11.5±2.5	10.9 ± 2.2	
Propofol (12.5 mg/kg,sc)	$10.4{\pm}2.1$	13±4	12±3	12.2±2.5	12±3	12±3	
Propofol (25 mg/kg, sc)	10.7 ± 1.0	12±3	28 ± 5^{be}	24 ± 5^{be}	16 ± 4^{be}	10.8 ± 1.3	
Propofol (50 mg/kg, sc)	12±3	14 ± 4	35 ± 8^{cf}	30 ± 9^{cf}	20 ± 4^{be}	14 ± 3	
Normal saline (ith)	$11.2{\pm}2.0$	11.2±2.6	10.8±1.5	12.2±2.7	12±3	12±3	
Intralipid (ith)	10.2±1.3	12.1±2.3	12±3	10.8 ± 1.5	11.8 ± 2.3	10.8 ± 1.3	
Propofol (5 µg, ith)	10.9 ± 2.3	10±3	13±4	11.1±2.2	12.4±1.8	11±3	
Propofol (10 µg, ith)	11.6±1.7	10.8±2.9	27 ± 5^{ci}	20 ± 4^{bi}	16 ± 5^{bh}	12±4	
Propofol (20 µg, ith)	10.8±1.3	13±3	32±6 ^{ci}	28 ± 6^{ci}	18 ± 4^{bh}	14 ± 3	
Normal saline (icv)	11.9±1.5	10.5±2.2	10.8±2.2	10.8 ± 2.3	10.6 ± 2.0	11±3	
Intralipid (icv)	10.8 ± 1.3	11.7±2.3	10.9±1.9	13±4	12.1±2.3	10.8 ± 1.2	
Propofol (5 µg, icv)	$11.4{\pm}1.6$	11±3	10.8±1.5	11±3	11.4±1.6	11.5±1.3	
Propofol (10 µg, icv)	10.1±2.1	10.5±2.2	10.5±2.2	10.5 ± 2.2	10.1 ± 2.1	10.5 ± 2.2	
Propofol (20 µg, icv)	11.5±1.8	10.9±1.3	13±3	11.8±1.3	11.5±1.8	11±1.3	

the TFL in a dose- and time-dependent manner 10–30 min after its injection(P < 0.05 or P < 0.01 vs NS, Table 1).

No significant difference existed in the number of writhing mice, writhing latency writhing times before and after sc, ith, or icv injection of 10% intralipid. Propofol (12.5 mg/kg, sc) and propofol (5 μ g, ith) showed no anti-nociceptive effect in acetic acid-induced writhing test. But propofol (25 and 50 mg/kg, sc) and propofol (10 and 20 μ g, ith) significant reduced the writhing times in a dose-dependent way (sc or ith) group (*P*<0.05 or *P*<0.01 vs NS, Table 2). Icv propofol (10, 20, and 40 μ g) did not produce any antinociceptive effects in the tail-immersion test and acetic acid-induced writhing test (*P*>0.05, Table 1, 2).

Effects of intrathecal prazosin and yohimbine on TFL in conscious mice in tail-immersion test No significant difference existed in the TFL between NS group and Me₂SO group (P>0.05, Table 3). Ith prazosin (5 and 10 µg) or yohimbine (5 and 10 µg) alone had no effect on the general behavior and TFL. However, mice in prazosin (20 µg) and yohimbine (20 µg) groups exhibited less movement and the muscle strength of hindlimbs decreased at least for 1 h followed by a full recovery. The TFL in prazosin 20 µg and yohimbine 20 µg groups was significantly shortened, compared with its own baseline and NS group (P<0.05, Table 3). Therefore, prazosin (5 and 10 µg) and yohimbine (5 and 10 µg) were used in the subsequent antinociceptive studies of propofol. **Table 2.** Effect of propofol on acetic acid-induced writhing in mice. n=12. Mean±SD. ^bP<0.05, ^cP<0.01 vs NS (sc). ^eP<0.05, ^fP<0.01 vs NS (ith).

Groups	Writhing latency/min	Writhing times	Number of Writhing mice
Normal Saline (sc)	3.8 ± 0.9	44 ± 10	12/12
Intralipid (sc)	3.2 ± 0.7	43±11	12/12
Propofol (12.5 mg/kg, sc)	$3.2{\pm}0.5$	34±11	12/12
Propofol (25 mg/kg, sc)	3.8 ± 0.9	28 ± 9^{b}	11/12
Propofol (50 mg/kg, sc)	3.9±1.0	$15\pm4^{\circ}$	10/12
Normal Saline (ith)	3.5 ± 1.0	43±10	12/12
Intralipid (ith)	$4.0{\pm}0.9$	45±11	12/12
Propofol (5 µg, ith)	3.8 ± 0.9	38±12	12/12
Propofol (10 µg, ith)	4.1 ± 1.0	27 ± 9^{e}	11/12
Propofol (20 µg, ith)	3.8 ± 0.6	$16\pm5^{\rm f}$	10/12
Normal Saline (icv)	$3.7{\pm}0.5$	44±12	12/12
Intralipid (icv)	$4.0{\pm}0.9$	43±11	12/12
Propofol (5 µg, icv)	3.6±0.9	38±10	12/12
Propofol (10 µg, icv)	3.1±0.6	42±12	12/12
Propofol (20 µg, icv)	3.9±0.5	40±13	12/12

Effects of pretreatment with intrathecal prazosin and yohimbine on TFL in propofol (50 mg/kg, sc)-treated mice in tail-immersion test The mice were injected intrathecally

Groups	TFL/s						
	Before treated			After treated			
	Baseline	5 min	10 min	20 min	30 min	40 min	
NS	11.9±1.6	12±3	11.8 ± 1.5	11.3 ± 1.4	11.4 ± 2.1	11.8 ± 1.7	
Me ₂ SO	11.1±2.3	11.5±2.2	10.7 ± 1.2	10.9 ± 2.1	11.1 ± 1.1	12±3	
Prazosin 5 µg	12±3	$10.4{\pm}1.2$	10.8±1.5	11.1±2.1	11.3 ± 1.1	10.7±1.3	
Prazosin 10 µg	10.9 ± 1.5	10.5±1.3	11±3	10.8 ± 1.7	10.5±1.6	$10.4{\pm}2.0$	
Prazosin 20 µg	10.8 ± 1.7	7.9±1.2 ^{be}	6.8±1.3 ^{be}	$7.8{\pm}0.5^{be}$	$8.3 {\pm} 1.4^{bc}$	9.5±1.0	
Yohimbine 5 µg	11.1±2.3	11.5±2.4	10.7±1.2	10.9 ± 2.1	11.1±1.1	10.9 ± 2.0	
Yohimbine 10 µg	10.7±1.6	10.9±1.5	12±3	11.7±1.7	11.3±1.6	11.4±1.3	
Yohimbine 20 µg	10.9±1.5	7.2±0.9 ^{be}	8.3±1.3 be	$8.6{\pm}0.7^{be}$	7.6±0.7 ^{bc}	9.8±0.8	

Table 3. Changes of tail-flick latency (TFL) after intrathecal prazosin or yohimbine in tail-immersion test in conscious mice. n=10. Mean±SD. ${}^{b}P<0.05 vs$ baseline. ${}^{e}P<0.05 vs$ NS.

with NS, Me₂SO, prazosin, or yohimbine at different doses 10 min before sc propofol. No significant differences existed in the TFL between NS group and Me₂SO group. Pretreatment with ith prazosin (5, 10 μ g) and yohimbine (5, 10 μ g) significantly decreased the TFL 10-30 min after propofol injection with the doses of prazosin and yohimbine increasing (*P*<0.05 vs NS, Table 5).

Effects of pretreatment with 6-OHDA on TFL in conscious mice and propofol (50 mg/kg, sc)-treated mice in tail-immersion test Mice in the 6-OHDA (20 μ g) alone group exhibited biting and scratching behavior and the TFL significantly decreased in comparison with its own baseline and the NS group (*P*<0.05, Table 4). No change in behavior and TFL was observed after treatment with ith NS, vehicle or 6-OHDA (5, 10 μ g) in conscious mice. However, pretreatment with ith 6-OHDA (5, 10 μ g) significantly decreased the TFL 10–30 min after propofol treatment with the dose of 6-OHDA increasing (*P*<0.05 vs NS, Figure 1).

Discussion

In attempting to eluciate the mechanisms for the antinociceptive effect of propofol, it is important to obviate sedation that can exert on the antinociceptive assay. In the present study, we found that the hypnotic and antinociceptive effects of propofol were temporarily uncoupled. In addition, the anesthetic on awareness was clearly supraspinal. Ith 6-OHDA, prazosin, or yohimbine significantly inhibited the antinociception of propofol but not consciousness of animals. Furthermore, we used the heat tail-flick assay, which measures the latency of a spinal withdraw reflex to noxious heat, which is independent of hypnotic-induced decrement in purposeful movement. These results indicated that propofolinduced prolongation of TFL observed in the present study was a result of antinociception but not sedation.

Propofol (50 mg/kg, sc) produced a motor block 2–5 min after injection, but there was no significant increase in TFL. Furthermore, Kerz T *et al* have suggested that immobility

Table 4. Changes of tail-flick latency (TFL) after intrathecal 6- hydroxydopamine (6-OHDA) in tail-immersion test in conscious mice. n=10. Mean±SD. ${}^{b}P<0.05 vs$ baseline. ${}^{e}P<0.05 vs$ vehicle.

Groups	TFL/s								
	Before treated			After treated					
	Baseline	5 min	10 min	20 min	30 min	40 min			
NS	11.6±1.4	10.2±1.9	12±3	10.9±1.9	11.8±2.3	11.2±1.7			
Vehicle	$10.8{\pm}2.1$	11.2 ± 1.8	10.6±1.4	10.7 ± 2.1	11.4±2.5	10.5±1.9			
6-OHDA 5 μg	10.5 ± 1.8	11.8±2.3	10.9±1.5	12 ± 3	11.7±2.5	10.9 ± 1.2			
6-OHDA 10 μg	11.7 ± 1.8	11.2±1.9	10.8±1.3	10.9 ± 1.7	10.8 ± 2.3	10.6±1.6			
6-OHDA 20 μg	10.5±1.4	7.5±0.9 ^{be}	6.8±1.4 ^{be}	6.9±1.1 ^{be}	7.2±1.2 ^{be}	6.8 ± 1.0^{b}			

Groups	TFL/s								
	Before treated		After t	reated					
	Baseline	5 min	10 min	20 min	30 min				
NS	10.8±1.3	12±3	31±7°	27±4°	22±5 ^b				
Me ₂ SO	11.2±2.3	11±3	29±7°	26±4°	21 ± 4^{b}				
Prazosin 5 µg	11.1±2.3	11.5±1.8	23 ± 4^{be}	19 ± 4^{be}	19±3 ^{be}				
Prazosin 10 µg	10.5 ± 2.4	13±4	17 ± 4^{bf}	16 ± 3^{bf}	15±3 ^{be}				
Yohimbine 5 µg	10.5±1.6	14.3±1.6	23 ± 4^{be}	18.9±1.5 ^{be}	17.7±2.7 ^{be}				
Yohimbine 10 µg	10.9±1.5	12.6±1.9	18 ± 5^{bf}	16.2±1.2 ^{bf}	14.5±2.1 ^{bf}				

Table 5. Effect of pretreatment with intrathecal prazosin or yohimbine on the antinociception of propofol (50 mg/kg, sc) in tail-immersion test on mice. n=10. Mean±SD. $^{b}P<0.05$, $^{c}P<0.01$ vs baseline. $^{e}P<0.05$, $^{f}P<0.01$ vs NS.



Figure 1. Effect of pretreatment with intrathecal 6-hydroxydopamine (6-OHDA) on the antinociception of propofol (50 mg/kg, sc) in tail-immersion test on mice. n=10. Mean±SD. ^bP<0.05, ^cP<0.01 vs baseline (0 min). ^eP<0.05, ^fP<0.01 vs NS.

during propofol anesthesia was not caused by a depression of spinal motoneuron circuit excitability^[13]. In addition, pretreatment with ith 6-OHDA, prazosin, or yohimbine inhibited the antinociception of propofol but not propofol-induced motor impairment. Therefore, it is not probable that motor nerve conduction block affects TFL nonspecifically.

In the present study, propofol (25 and 50 mg/kg, sc) caused no noticeable sedation 30 min after its injection, but dose-dependently decreased the writhing times in the acetic-acid writhing test on mice. Therefore, these results suggested that systemic propofol also inhibited the chemical stimulation. The same results were shown in a previous study ^[2]. However, propofol had no effect on the writhing latency, which suggested that the antinociceptive effect of propofol at subanesthesia doses on inflammatory pain might be not very strong. In the present study, systemic propofol (25 and 50 mg/ kg, sc) and propofol (10 and 20 μ g, ith) displayed a doseand time-dependent antinociceptive effect. However, icv propofol did not produce any antinociceptive effects. Taken together, these results suggest that propofol produced antinociception at the spinal level but not at the supraspinal sites.

Ith 6-OHDA (20 µg) treatment for 3 d, which markedly depleted NE contents by more than 90% but not serotonin in the spinal cord study^[12], significantly shortened the basal TFL in conscious mice in our study. Additionally, $\alpha_1 R$ antagonist prazosin (20 μ g, ith) or $\alpha_2 R$ antagonist yohimbine (20 µg, ith) alone significantly shortened the basal TFL. These results supported the previous finding that noradrenergic synaptic transmission was important in pain sensory processing in the spinal dorsal horn. The effect of ith high dose of yohimbine on tail response was consistent with the conclusion that NE mediated the inhibition of nociception by $\alpha_2 Rs$ in the spinal cord. The reduction of TFL after ith higher dose of prazosin suggested that spinal α_1 Rs also contributed to the pain sensory modulation, which agrees with the purpose that NE mediated the inhibition of nociception by activation of $\alpha_1 Rs$ located on inhibitory interneurons^[8,9]. This possibility is supported by several studies which demonstrated that ith $\alpha_1 R$ agonist activated dorsal horn to produce antinociception. For example ith selective $\alpha_1 R$ agonists, such as methoxamine^[14,15] and phenylephrine^[16] produced antinociception that could be reduced by pretreatment with ith $\alpha_1 R$ antagonist prazosin^[14,15].

Pretreatment with ith 6-OHDA (5 and 10 μ g), which markedly depleted NE contents in the spinal cord, significantly attenuated the antinociception of propofol. Furthermore, pretreatment with ith α_1 R antagonist prazosin or α_2 R antagonist yohimbine significantly inhibited the antinociception of sc propofol in tail-immersion test. Therefore, these results strongly indicated that spinal noradrenergic system had a significant modulatory role in propofol antinociception. However, ith 6-OHDA, prazosin and yohimbine did not completely reverse the antinociception of propofol. This suggested that other mechanisms, such as an excitation of spinal GABA_A receptors^[1] and an inhibition of spinal NMDA, AMPA receptors^[2], contributed to antinociception of propofol. In the present study, we used only $\alpha_1 R$ and $\alpha_2 R$ antagonists; therefore it was unclear whether propofol could bind directly with $\alpha_1 Rs$ or $\alpha_2 Rs$ in the spinal cord.

Taken together, our data suggest that systemic propofol activates the central noradrenergic system to produce antinociception, which increases the spinal release of NE and results in an antinociceptive effect via $\alpha_1 Rs$ and $\alpha_2 Rs$ in the spinal cord. To further prove this speculation, a direct measurement of the spinal release of NE induced by propofol will be necessary in the near future.

References

- Nadeson R, Goodchid CS. Antinociceptive properties of propofol: involvement of spinal cord gamma-aminobutyric acid (A) receptors. J Pharmacol Exp Ther 1997; 282: 1181–6.
- 2 Xu AJ, Duan SM, Zeng YM. Effects of intrathecal NMDA and AMPA receptors agonists or antagonists on antinociception of propofol. Acta Pharmacol Sin 2004; 25: 9–14.
- 3 Antognini JF, Wang XW, Piercy M, Carstens E. Propofol directly depresses lumbar dorsal horn neuronal responses to noxious stimulation in goats. Can J Anaesth 2000; 47: 273–9.
- 4 Anwar MM, Abdel-Rahman MS. Effect of propofol on perception of pain in mice: mechanisms of action. Comp Biochem Physiol A Mol Integr Physiol 1998; 120: 249–53.
- 5 Fang F, Proudfit HK. Antinociception produced by microinjection of morphine in the rat periaqueductal gray is enhanced in the foot, but not the tail, by intrathecal injection of alpha1-adrenoceptor antagonists. Brain Res 1998; 790: 14–24.

- 6 Feng CY, McAdoo DJ, Willis WD. Periaqueductal gray stimulationinduced inhibition of nociceptive dorsal horn neurons in rats is associated with the release of norepinephrine, serotonin, and amino acids. J Pharmacol Exp Ther 1999; 289: 868–76.
- 7 Pan YZ, Li DP, Pan HL. Inhibition of glutamatergic synaptic input to spinal Lamina II_o neurons by presynaptic α₂-adrenergic receptors. J Neurophysiol 2002; 87: 1938–47.
- 8 Baba H, Shimoji K, Yoshimura M. Norepinephrine facilitates inhibitory transmission in substantia gelatinosa of adult rat spinal cord (part 1): effects on axon terminals of GABAergic and glycinergic neurons. Anesthesiology 2000; 92: 473–84.
- 9 Baba H, Goldstein PA, Okamoto M, Kohno T, Ataka T, Yoshimura M, et al. Norepinephrine facilitates inhibitory transmission in substantia gelatinosa of adult rat spinal cord (part 2): effects on somatodendritic sites of GABAergic neurons. Anesthesiology 2000; 92: 485–92.
- 10 Zhang CY, Zhu TJ, Hu GX, Chen XY, Liu DX, Chen ZK. Effect of sodium dimercaptopropanesulfonate on antagonism of tetramethylenedisulphotetramine to GABA receptor. Acta Pharmacol Sin 2001; 22: 435–9.
- 11 Xu SY, Bian RL, Chen X. Methodology of pharmacological experiments. 3 rd ed. Beijing: People's Medical Publishing House; 2002. p 882–7.
- 12 Hung KC, Wu HE, Mizoguchi H, Leitermann R, Tseng LF. Intrathecal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine blocks the antinociception induced by endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse. J Pharmacol Sci 2003; 93: 299–306.
- 13 Kerz T, Hennes HJ, Feve A, Decq P, Filipetti P, Duvaldestin P. Effects of propofol on H-reflex in humans. Anesthesiology 2001; 94: 32–7.
- 14 Loomis CW, Arunachalam KD. Intrathecal St-587: effects on nociceptive reflexes and blood pressure in the rat. J Pharmacol Exp Ther 1992; 263: 428–35.
- 15 Howe JR, Wang JY, Yaksh TL. Selective antagonism of the antinociceptive effect of intrathecally applied alpha adrenergic agonists by intrathecal prazosin and intrathecal yohimbine. J Pharmacol Exp Ther 1983; 224: 552–8.
- 16 Aran S, Proudfit HK. Antinociceptive interactions between intrathecally administered alpha noradrenergic agonists and 5'-*N*-ethylcarboxamide adenosine. Brain Res 1990; 519: 287–93.